Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154645 · ClinicalTrials.gov registry record · Phase 1
Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy
A Phase 1 study of Acute Mountain Sickness, sponsored by Grant S Lipman.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT03154645 is a Phase 1 study of Acute Mountain Sickness that has completed, run by Grant S Lipman. The registered enrollment target is 92 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03154645, a Phase 1 study of Acute Mountain Sickness, has completed, sponsored by Grant S Lipman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.
Conditions Studied
Interventions
- DRUG Ibuprofen
- DRUG Acetazolamide
Study Locations (1)
California
- White Mountain Research Station - Bishop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2017-08-12 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154645
The ClinicalTrials.gov registry entry for NCT03154645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grant S Lipman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Mountain Sickness appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen is the first listed.
NCT03154645 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03154645 about?
NCT03154645 is a clinical study titled "Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy". This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment ...
What is the current status of trial NCT03154645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2017-08-12. Estimated completion is 2017-10-01.
What conditions does trial NCT03154645 study?
This clinical trial studies the following conditions: Acute Mountain Sickness.
What interventions are being tested in trial NCT03154645?
The interventions under investigation include: Ibuprofen (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03154645?
This trial is sponsored by Grant S Lipman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03154645 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Mountain Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.